Lupus

The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.

For patients with diseases such as lupus or rheumatoid arthritis who take low-dose drugs at lower frequencies, the relief afforded by over-the-counter drugs such as ibuprofen and naproxen can be a boon.

The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.

Physical exercise “should be considered” in patients with either systemic lupus erythematosus or systemic sclerosis, according to new EULAR recommendations on non-pharmacologic management published in the Annals of the Rheumatic Diseases.

A woman diagnosed with schizophrenia and psychosis who was nonverbal and nonresponsive for 2 decades recently “woke” after treatment with pulse steroids and cyclophosphamide.

A program using cognitive behavioral and mindfulness meditation techniques demonstrated early potential to ease fatigue, depression and pain symptoms in childhood-onset systemic lupus erythematosus, according to researchers.

SAN DIEGO —The recent voclosporin approval and continued research into cell therapies make this a “very exciting time” for lupus nephritis therapy, according to a speaker 2023 Congress of Clinical Rheumatology West.

SAN DIEGO — Although genetics heavily influence patient risk for developing lupus, it is critical to also be aware of “environmental and lifestyle factors,” according to a speaker at the Congress of Clinical Rheumatology West 2023 meeting.

Patients who have been hospitalized with systemic lupus erythematous demonstrate an increased risk for multiple cancer subtypes, as well as an increased risk for 5-year mortality after cancer development, according to data.

Highlights of the upcoming 2023 Congress of Clinical Rheumatology-West include a talk on what the rheumatology field will look like in a decade, according to David A. McLain, MD, symposium director for the meeting.